biOracle
Bringing Preventive Care to Life

 

Search Our site
Search Our site
 

Latest Company News...

Visit us at Medica 2009, 18 -21 November, Hall 16, Stand F04-7... 

>> Read Latest biOracle News Here

 

Why Treat when you can Prevent ?

   Home | About Us | Products | Opportunities | News | Contact Us | Location

Latest Company News

 

Wednesday 11 November, 2009. BiOracle will be exhibiting at Medica 2009, Düsseldorf. See us at Hall 16 Stand F04-7 More details...

Monday 20 July, 2009. BiOracle appoints Natucare as distributor of Canditect, its rapid point-of-care diagnostic test for candida infection, in Asia. More details...

Monday 9 March, 2009. BiOracle appoints Clini Care as distributor of Canditect, its rapid point-of-care diagnostic test for candida infection, in Greece. More details...

Friday 3 February, 2006. Latest clinical data on BiOracle's diagnostic test for candida demonstrates that it is more effective than culture and microscopy in the diagnosis of vaginal candidiasis (thrush) . More details...

Tuesday 6 September, 2005. Hygis SA launches BiOracle's diagnostic test for candida in Switzerland as "Hygis Test Candidose". More details...

Monday 11 April, 2005. BiOracle appoints Hygis SA as distributor of its rapid point-of-care diagnostic test for candida infection in Switzerland. More details...

15 October 2004. BiOracle announces restructuring of its senior management team. More details...

6 April 2004. BiOracle's novel point-of-care diagnostic test for Acute Appendicitis featured in the Daily Mail. More details...

29 March 2004. DMI Biosciences Inc announces license agreement with BiOracle Ltd for novel point-of-care diagnostic test for Acute Appendicitis. More details...

15 March 2004. BiOracle Ltd and SensAm Ltd enter into a collaborative agreement to develop and market an important new point-of-care test for the detection of H. pylori. More details...

11 March 2004. BiOracle Ltd enters into an agreement with DMI Biosciences Inc to acquire DMI's point-of-care diagnostic test for thrush.  More details...

1 May 2003. BiOracle launches as a new healthcare company focusing on preventive care. More details....

 

 

 

 

 

 


Wednesday 11 November, 2009. BiOracle will be exhibiting at Medica 2009.

BiOracle will be exhibiting at this year's Medica, as part of the British Pavilion. Visit us at Stand F04-7 in Hall 16 from 18 - 21 November.

We are seeking to expand our distributor network for Canditect, a rapid point-of-care diagnostic test for candida infection. We are also seeking partners to develop and commercialise Appytest, an innovative rapid test for Appendicitis.

If you would like to arrange a specific meeting time, please contact us in advance of Medica, or visit our Stand at any time during the Event.

 

 

 

 

Source: BiOracle Limited

 

 

Monday 20 July, 2009. BiOracle appoints Natucare as distributor of Canditect, its rapid point-of-care diagnostic test for candida infection, in Asia.

BiOracle has appointed Natucare Asia Limited as distributor of Canditect in Thailand and other markets across Asia.

Natucare, a newly-established company specialising in female healthcare products, will introduce Canditect in Thailand and then progressively across other markets in Asia.

 

 

 

Source: BiOracle Limited

 

 

Monday 9 March, 2009. BiOracle appoints Clini Care as distributor of Canditect, its rapid point-of-care diagnostic test for candida infection, in Greece.

BiOracle has appointed Clini Care EPE as distributor of Canditect in Greece.

Clini Care supplies a range of innovative products to the Greek healthcare market and will introduce Canditect through its existing distribution channels.

 

 

 

Source: BiOracle Limited

 

 

Friday 3 February, 2006. Latest clinical data on BiOracle's diagnostic test for candida demonstrates that it is more effective than culture and microscopy in the diagnosis of vaginal candidiasis (thrush).

Clinical evaluation of YeasTest, BiOracle's point-of-care diagnostic test for vaginal candidiasis (thrush) has shown that the test is more sensitive and also more specific for candida infection than either culture or microscopy, the two most commonly used diagnostic techniques for vaginitis.

In the study, YeasTest had sensitivity of 85.1% (compared to 74.6% for culture and 58.7% for microscopy) and specificity of 92.6% (compared to 88.0% for culture and 85.5% for microscopy). YeasTest's overall efficiency rating was 91.5% (compared to 85.9% for culture and 78.2% for microscopy).

High diagnostic accuracy, allied to YeasTest's convenience and ease of use at the point of care, make it an ideal diagnostic test for use by a range of healthcare practitioners as an aid to the diagnosis of vulvovaginal candidiasis.

Further details are available from BiOracle on request.

Source: BiOracle Limited

 

 

Tuesday 6 September, 2005. Hygis SA launches BiOracle's diagnostic test for candida in Switzerland as "Hygis Test Candidose".

Hygis SA has now launched BiOracle’s new rapid diagnostic test for vaginal candidiasis in Switzerland and Liechtenstein as “Hygis Test Candidose”.

With its rapid, point-of-care test format, Hygis Test Candidose combines excellent diagnostic accuracy with much greater convenience compared to other standard diagnostic techniques. Consequently, Hygis Test Candidose offers significant benefits to both healthcare practitioners and to patients.

BiOracle Limited is a privately-held healthcare company based in the North West of England, that commercialises innovative healthcare products with a focus on preventive care.

Hygis SA is a private Swiss healthcare company distributing innovative niche healthcare products throughout Switzerland. Hygis’s primary focus is on Gynaecology and myorelaxants.

Source: BiOracle Limited

 

 

Monday 11 April, 2005. BiOracle Appoints Hygis SA as distributor of its rapid point-of-care diagnostic test for candida infection in Switzerland

BiOracle Limited (BiOracle, www.bioracle.co.uk) announced today the appointment of Hygis SA as a distributor of its rapid point-of-care diagnostic test for candida infection. The agreement covers the territories of Switzerland and Liechtenstein.

Vaginal candidiasis (also known as thrush) affects three-quarters of all women at least once in their lives. In one in five cases, women experience a more persistent form of the condition, known as recurrent thrush. Diagnosis of candida infection is typically confirmed by microscopic examination or by culturing from a vaginal sample. Neither method can deliver the speed and accuracy of diagnosis required in today's demanding healthcare environment. Candidiasis can often be confused with other forms of vaginitis, including bacterial vaginitis, resulting in inappropriate treatment and unnecessary discomfort for the patient.

BiOracle's new diagnostic test delivers high diagnostic accuracy in a test format that can simply and rapidly be used at the point of care, offering significant benefits for doctors and patients alike.

"There is an excellent fit between Hygis's existing female health business and our rapid diagnostic test for vaginal candidiasis," said Michael Spencer, CEO of BiOracle. "We are delighted to be working with Hygis to bring this exciting new product to a wider audience, helping to broaden the 'test and treat' paradigm into another medical condition".

"Hygis is already very active in the prevention and cure of vaginal infections. Adding BiOracle's excellent rapid diagnostic test will be of great help to our customers in their battle against candidiasis" said Denis Ammann, CEO of Hygis.

BiOracle Limited is a privately-held healthcare company based in the North West of England, that commercialises innovative healthcare products with a focus on preventive care.

Hygis SA is a private Swiss healthcare company distributing innovative niche healthcare products throughout Switzerland. Hygis's primary focus is on Gynaecology and myorelaxants.

Source: BiOracle Limited

 

 

15 October 2004. BiOracle announces restructuring of its senior management team. 

The Board of Directors of BiOracle Ltd announce that CEO, Bruce Murdoch, is standing down with immediate effect to pursue other interests. He will remain on the Board as a non-executive director. 

Michael Spencer, currently a non-executive director of BiOracle is appointed CEO of the company. Michael was previously a partner in Accenture plc's Health and Life Sciences practice and held a number of senior positions during his 15 year tenure there. His roles mainly focused on the Regulatory and Clinical Development areas, and the Commercial to R&D interface. BiOracle intends to utilise Michael's programme management experience and network of contacts within the industry. 

John Clinton assumes additional responsibilities as Commercial Director.

Artie Chalmers remains as Finance Director.

Commenting on the recent changes, Michael Spencer said that we are now in a position to take our company forward to implementation through a series of licensing deals.

BiOracle is a Cheshire, UK based company, which licenses and markets a range of "point of care" diagnostic products. For further information see www.bioracle.co.uk

 

Click here for further background on biOracle.

 

 

6 April 2004. BiOracle's novel point-of-care diagnostic test for Acute Appendicitis featured in the Daily Mail. 

The following article was featured in the UK's Daily Mail newspaper. 

How to beat appendix op
by PAT HAGAN, Daily Mail

new test for appendicitis could save hundreds of patients from unnecessary operations. The simple test looks for a marker in urine that indicates whether severe stomach pain is really being caused by an inflamed appendix.

If the marker is present, surgeons can operate quickly to remove the organ. If it's not present, they know something else is causing the pain.

Current diagnostic techniques are far from perfect because many diseases can cause the same symptoms as appendicitis. In as many as 30 per cent of cases, surgeons open up a patient only to find their appendix is perfectly healthy.

The appendix is a small worm-like pouch attached to the large bowel. Its exact function remains unknown but it can become inflamed, causing waves of pain in the abdomen. After a few hours the pain worsens, temperature soars and the patient feels sick.

Agony of appendicitis

Most patients with appendicitis turn up at casualty departments in agony. Doctors usually take a medical history and a blood or urine sample to check for raised white blood cell count - a sign of infection.

They also examine the abdomen by pressing on it to see where the pain is coming from. The most common cure is an operation that involves making a two-inch incision in the lower part of the abdomen and removing the appendix under a general anaesthetic. Most patients need to stay in hospital for up to three days afterwards.

Actress Kate Beckinsale recently suffered appendicitis and was rushed to hospital in LA. She underwent an emergency operation and has now recovered completely.

The new test works by looking for a specific chemical which is released by the organism that triggers appendicitis. This can be detected in the urine of an affected person within hours of the first symptoms.

Test takes 15 minutes

The urine test takes just 15 minutes and is expected to be available in the UK early next year. It is hoped A&E departments will stock it in order to help doctors accurately diagnose the condition.

Called Appytest, it is designed to be used as a back-up to blood checks. BiOracle Limited, a Cheshire-based firm that will be marketing the product in the UK, says it is easy to use, cheap and accurate.

"It takes about 15 minutes and will be very affordable," says company spokesman Bruce Murdoch. "None of these kind of tests are completely foolproof, but ours is 80 to 90 per cent accurate.

"If a test result comes back negative and the white blood-cell count is also negative, then we would advise keeping the patient under observation for 24 hours. Because the test will be cheap, it can be repeated after a few hours."

Source: http://www.femail.co.uk/pages/standard/article.html?in_article_id=211050&in_page_id=169

 

 

29 March 2004. DMI Biosciences Inc announces license agreement with biOracle Ltd for novel point-of-care diagnostic test for Acute Appendicitis.

Monday March 29, 2004, Englewood, Colorado – DMI BioSciences, Inc. (DMI, www.dmibiosciences.com) announced today the licensing of its novel point-of-care diagnostic test (APPYTEST®) for acute appendicitis to BiOracle, Ltd. (www.bioracle.co.uk).  BiOracle was granted exclusive, worldwide rights to develop and commercialize DMI’s patented technology; DMI will receive milestone payments and royalties.

Appendicitis is the most common surgical emergency requiring an operation, yet early diagnostic assessment relies mainly on physical examination and signs and symptoms that can be misleading. The new test for appendicitis will provide clinicians with a rapid, non-invasive assay that is easy to administer, has high diagnostic specificity and can potentially reduce unnecessary hospitalizations and surgeries.  At present, no rapid diagnostic biomarker has high diagnostic specificity for acute appendicitis.  

Pictured at the signing of the license agreement in Manchester, UK, are DMI Biociences President and CEO, Bruce Millar and biOracle CEO, Bruce Murdoch
“BiOracle has a very experienced team rapidly building a portfolio of preventive care products for global markets,” said Bruce Miller, President and CEO of DMI. “We are pleased that BiOracle is commercializing a test we believe will significantly improve patient care while reducing healthcare costs.”
Also present at the signing were Kevin Bilyard and Robert Shaw of biOracle.

DMI BioSciences, Inc. is a privately-held biopharmaceutical company based in Englewood, Colorado, that discovers and develops small molecule and peptide-based pharmaceuticals and biomarkers for acute and chronic inflammation. DMI focuses on immunologic, vascular and CNS diseases, including acute coronary syndrome, multiple sclerosis, Alzheimer’s disease, asthma and cancer. DMI is co-developing several of its drug candidates with industry partners. Two of DMI’s drug candidates are currently in human clinical trials. DMI’s strategy is to develop pharmaceutical compounds and biomarkers through preclinical and early-stage clinical development and collaborate with financial and industry partners for later-stage development and commercialization.

Except for the historical information presented, matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words “will”; “believes”; “should”; “intends”;  “anticipates”; “plans”; “expects”; “estimates”; or similar statements are forward-looking statements.  Forward looking statements include statements about the potential benefits of the license agreement between BiOracle, Ltd. and DMI BioSciences, the use of the APPYTEST® technology, either alone or in conjunction with other biomarkers, as a diagnostic tool to aid in the diagnosis of acute appendicitis.  Risks and uncertainties include risks regarding the product development process generally, risks associated with the introduction of competitive products from companies with greater capital and resources, expansion or development of a direct sales effort in domestic and international markets, and risks and expenses associated with litigation, contract disputes, patent conflicts, product recalls, manufacturing constraints, backlog, delays or inefficiencies, shipment problems, seasonal customer demand, the timing of significant orders, changes in reimbursement policies, regulatory changes, competitive pressures on average selling prices, risks associated with the development and commercialization of new products.  DMI BioSciences disclaims any intent or obligation to update these forward-looking statements.

 

Source: DMI BioSciences, Inc.

Email: info@dmibiosciences.com

Website: www.dmibiosciences.com

 

 

15 March 2004. BiOracle Ltd and SensAm Ltd enter into a collaborative agreement to develop and market an important new point-of-care test for the detection of H. pylori.

BiOracle Ltd and Sensam Ltd have today entered into a collaborative agreement to jointly develop and market a new test for the detection of H. pylori based on proprietary technology initially developed by SensAm.

Further details will be published here at a later date.

 

 

 

 

11 March 2004. BiOracle Ltd enters into an agreement with DMI Biosciences Inc to acquire DMI's point-of-care diagnostic test for thrush.

BiOracle Ltd and DMI Biosciences Inc have today entered into an agreement whereby BiOracle Ltd has acquired DMI's point-of-care diagnostic test for thrush.

The test, based on proprietary technology originally developed by DMI, detects the presence of candida, the organism that causes thrush, in a simple test that can be used rapidly at the point-of-care.

The test is already being marketed in Italy, Spain and Portugal under the terms of a previous agreement by Shire Pharmaceuticals Group plc.

Further details will be published here at a later date.

 

 

 

1 May 2003. biOracle launches as a new healthcare company focusing on preventive care.

biOracle was officially launched by its founders today as a new player in the emerging field of preventive care.

biOracle will focus on late-stage development and commercialisation of preventive care products for niches of unmet medical need.

CEO Bruce Murdoch noted that biOracle was in discussion with a number of possible partners about deals to give biOracle access to their products and technologies.

 

 

© Copyright 2009 BiOracle Limited. All Rights Reserved